HER2 overexpression is found in around 20 to 30% of breast cancers, representing an aggressive subtype associated with adverse clinicopathological features and poor prognosis, namely high recurrence rates, short disease-free survival, and short overall survival [14,15]. This evidence concerns the gene ERBB2 and breast cancer.